The efficacy of HDAC inhibitors has been demonstrated in vitro and in vivo models of JAK2 p. V617F-mutant MPN, particularly in combination with a JAK inhibitor (Wang et al., 2009; Akada et al., 2012; Evrot et al., 2013). Here, JAK2 is linked to myeloproliferative disorder.